SpectraWAVE Expands Company Leadership, Appointing Two New Vice Presidents to Executive Team

• Vivek Walimbe, Ph.D., former VP for Baxter Healthcare, to lead development of intracoronary imaging product and expand portfolio
• Farzad Parsaie, with three decades of med device leadership, to oversee Quality and Regulatory Affairs

BEDFORD, Mass.--(BUSINESS WIRE)--SpectraWAVE, Inc., a pre-commercial medical imaging company focused on optical and computational insights for the treatment and prevention of coronary artery disease, today announced the appointment of Vivek Walimbe, Ph.D., as Vice President of Research and Development, and Farzad Parsaie as Vice President of Quality and Regulatory Affairs. Dr. Walimbe and Parsaie, who join the company’s executive team, will lead the charge to regulatory approval of SpectraWAVE’s flagship intracoronary imaging technology, and expansion of the product portfolio.

“This past year has been an incredible period of growth and productivity for our company,” said Eman Namati, Ph.D., Chief Executive Officer of SpectraWAVE. “With a uniquely talented team, we have completed our pivotal pre-clinical study and are heading into the verification and validation phase. The additions of Vivek and Farzad to our executive team were carefully timed and represent our ambition to solidify our platform and further innovate and transform this space. Vivek’s background in imaging, along with a track record in leading high-performing teams, will ensure our flagship product completes the development process efficiently while working to expand our portfolio. Farzad’s extensive medical device background in quality, regulatory affairs, and operations, are essential as we scale towards global medical device manufacturing.”

Dr. Walimbe joins SpectraWAVE from Baxter Healthcare, where he served as Vice President of Research and Development, and was responsible for innovation, new product development, and lifecycle management for the $2.8B Medication Delivery business unit including broadening the focus from a single product to a world-class portfolio of connected infusion systems, monitoring technologies and digital software applications. Prior to Baxter Healthcare, Dr. Walimbe spent seven years at GE Healthcare in technical and leadership roles of increasing scope to help launch multiple imaging products and applications in global markets, followed by a role at Medtronic managing new product development programs. Dr. Walimbe has a Ph.D. from the Ohio State University, and performed his graduate research at Cleveland Clinic where he led the investigation of multimodality imaging application for improved diagnosis of coronary artery disease. He is the author or co-author of more than 15 patents and 25 scientific publications.

“The intracoronary imaging product that SpectraWAVE is developing is an amazing engineering feat, combining multiple imaging modalities without sacrificing the quality of either, all wrapped up in an incredible form factor coupled with an elegant, intuitive workflow,” said Dr. Walimbe. “Joining a fast paced and skilled team like this and taking part in the innovation process is incredibly exciting. I’m looking forward to working with the team to ensure we have the maximum impact on patients, both with the flagship product and our plans for expanding the portfolio.”

Parsaie comes to SpectraWAVE by way of Johnson & Johnson’s Robotics and Digital Solutions, where he was responsible for program management of hardware subsystems, advanced visualization, and new product introduction. Prior, Parsaie served at Levitronix initially as VP of RA and QA and then Chief Operating Officer. He then became Chief Operating Officer at GeNO, and finally President and CEO of Nido Surgical. Parsaie has an MBA from the MIT Sloan School of Management.

About SpectraWAVE, Inc.

SpectraWAVE, located in Bedford, MA, is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights for the treatment and prevention of coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events, with half of those adverse events caused by high risk plaques that were previously left untreated. The SpectraWAVE medical imaging platform is a state-of-the-art integration of proven imaging technologies - designed to help interventional cardiologists understand their patients and optimize interventions. For more information, please visit www.spectrawave.com.